Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Mani Akhtari, Sarah A. Milgrom, Chelsea C. Pinnix, Jay P. Reddy, Wenli Dong, Grace L. Smith, Osama Mawlawi, Zeinab Abou Yehia, Jillian Gunther, Eleanor M. Osborne, Therese Y. Andraos, Christine F. Wogan, Eric Rohren, Naveen Garg, Hubert Chuang, Joseph D. Khoury, Yasuhiro Oki, Michelle Fanale, Bouthaina S. Dabaja

Blood (2018) 131 (1): 84–94.

https://doi.org/10.1182/blood-2017-04-773838

Published: 2018

Journal Articles

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan M. Pinelli, Dana A. Kennedy, Andrei Shustov

Blood (2017) 130 (25): 2709–2717.

https://doi.org/10.1182/blood-2017-05-780049

Published: 2017

Includes: Supplemental data

Journal Articles

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

Joseph M. Connors, Stephen M. Ansell, Michelle Fanale, Steven I. Park, Anas Younes

Blood (2017) 130 (11): 1375–1377.

https://doi.org/10.1182/blood-2017-05-784678

Published: 2017

Journal Articles

New insights into NLPHL transformation

Michelle Fanale

Blood (2016) 127 (16): 1946–1947.

https://doi.org/10.1182/blood-2016-03-699108

Published: 2016

Journal Articles

SUV max on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy

Blood (2014) 124 (21): 1629.

https://doi.org/10.1182/blood.V124.21.1629.1629

Published: 2014

Journal Articles

Sequence Level Analysis of Hodgkin Lymphoma Clonotypes Detected in Peripheral Blood Using a Next-Generation Sequencing Approach

Yasuhiro Oki, MD, Sattva S. Neelapu, Michelle Fanale, Larry W. Kwak, MD PhD, Luis Fayad, MD, Maria Alma Rodriguez, Michael Wallace, Mark Klinger, Victoria Carlton, Katherine A Kong, Malek Faham, Anas Younes

Blood (2014) 124 (21): 1610.

https://doi.org/10.1182/blood.V124.21.1610.1610

Published: 2014

Journal Articles

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, MD, Michelle Fanale, MD, Ann LaCasce, MD, Ariela Noy, Paolo Caimi, MD, Samir Parekh, MD, John W Hayslip, MD, Deepa Jagadeesh, MD MPH, Raymond S Lord, Mary J Lechowicz, MD, Rakesh Gaur, MD, Andrea Lucas, RN, Louis M Staudt, MD PhD, Seth M. Steinberg, PhD, Brad Kahl, MD, Jonathan W. Friedberg, MD, Richard F Little, MPH, MD, Nancy L Bartlett, MD, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 395.

https://doi.org/10.1182/blood.V124.21.395.395

Published: 2014

Journal Articles

A novel prognostic scoring system for NLPHL

Michelle Fanale

Blood (2013) 122 (26): 4154–4155.

https://doi.org/10.1182/blood-2013-11-533109

Published: 2013

Journal Articles

Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients

Filip Janku, MD, PhD, Ignacio Garrido-Laguna, MD, Vivianne Velez-Bravo, Gerald S. Falchook, MD, Vivek Subbiah, MD, David S. Hong, MD, Yasuhiro Oki, MD, Jason R. Westin, MD, Cesar A. Nunez, M.D., Luis E Fayad, Larry W. Kwak, MD, PhD, Elizabeth J Shpall, MD, Jennifer J. Wheler, MD, Winnie Liang, PhD, Bodour Salhia, PhD, Funda Meric-Bernstam, MD, Razelle Kurzrock, Michelle Fanale, MD

Blood (2013) 122 (21): 3048.

https://doi.org/10.1182/blood.V122.21.3048.3048

Published: 2013

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

Jinsheng Weng, Seema Rawal, Fuliang Chu, Hyun Jun Park, Rakesh Sharma, David A. Delgado, Luis Fayad, Michelle Fanale, Jorge Romaguera, Amber Luong, Larry W. Kwak, Sattva S. Neelapu

Blood (2012) 120 (8): 1613–1623.

https://doi.org/10.1182/blood-2011-09-382838

Published: 2012

Includes: Supplemental data

Journal Articles

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Yasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, Luis E. Fayad, Michelle Fanale, Jorge Romaguera, Anas Younes

Blood (2012) 119 (9): 2171–2172.

https://doi.org/10.1182/blood-2011-11-391037

Published: 2012

Journal Articles

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

Michelle Fanale, MD, William I Bensinger, MD, John C. Byrd, MD, Brett Ewald, PhD, Daniel Carreon, PhD, Johan Baeck, MD, Arnold S. Freedman, MD

Blood (2011) 118 (21): 3702.

https://doi.org/10.1182/blood.V118.21.3702.3702

Published: 2011

Journal Articles

Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo

Felipe Samaniego, MD, Jillian F Wise, BS, Luis Fayad, MD, Michelle Fanale, MD, Fredrick Hagemeister, MD, Vijairam Selvaraj, MD, David M. Goldenberg, ScD, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD

Blood (2011) 118 (21): 1796.

https://doi.org/10.1182/blood.V118.21.1796.1796

Published: 2011

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.

Blood (2009) 114 (22): 1714.

https://doi.org/10.1182/blood.V114.22.1714.1714

Published: 2009

Journal Articles

Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.

Anas Younes, MD, Amanda R Copeland, MS, Jorge Romaguera, MD, Luis Fayad, MD, Michelle Fanale, M.D., Silvana de Castro Faria, MD, PhD, L. Jeffrey Medeiros, MD, Ph.D, S. Percy Ivy, MD

Blood (2009) 114 (22): 3744.

https://doi.org/10.1182/blood.V114.22.3744.3744

Published: 2009

Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD

Blood (2009) 114 (22): 3922.

https://doi.org/10.1182/blood.V114.22.3922.3922

Published: 2009

Journal Articles

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Anas Younes, MD, Leo Gordon, MD, Stella Kim, MD, Jorge Romaguera, MD, Amanda R Copeland, MS, Silvana de Castro Farial, MD, Larry Kwak, MD, PHD, Luis Fayad, MD, Frederick Hagemeister, MD, Michelle Fanale, M.D., John Lambert, PhD, Teresa Bagulho, MD, Rodica Morariu-Zamfir, MD

Blood (2009) 114 (22): 585.

https://doi.org/10.1182/blood.V114.22.585.585

Published: 2009

NARROW

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

New insights into NLPHL transformation

SUV max on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy

Sequence Level Analysis of Hodgkin Lymphoma Clonotypes Detected in Peripheral Blood Using a Next-Generation Sequencing Approach

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

A novel prognostic scoring system for NLPHL

Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,

Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only